Cogent Biosciences (NASDAQ: COGT)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.590 | -0.710 | -0.1200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cogent Biosciences (NASDAQ: COGT) through any online brokerage.
Other companies in Cogent Biosciences’s space includes: Avidity Biosciences (NASDAQ:RNA), Replimune Group (NASDAQ:REPL), Altimmune (NASDAQ:ALT), CareDx (NASDAQ:CDNA) and TG Therapeutics (NASDAQ:TGTX).
The latest price target for Cogent Biosciences (NASDAQ: COGT) was reported by Guggenheim on Tuesday, June 28, 2022. The analyst firm set a price target for 15.00 expecting COGT to fall to within 12 months (a possible -1.32% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Cogent Biosciences (NASDAQ: COGT) is $15.2 last updated August 18, 2022, 8:00 PM UTC.
There are no upcoming dividends for Cogent Biosciences.
Cogent Biosciences’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for Cogent Biosciences.
Cogent Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.